JAS-R, a new megakaryo-erythroid leukemic cell line that secretes erythropoietin. 2006

Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
Division of General Medicine, Aoto Hospital, Jikei University School of Medicine, Tokyo 125-8506, Japan.

BACKGROUND The processes of leukemogenesis and differentiation of the megakaryo-erythroid lineage remain poorly understood. Leukemic cell lines derived from megakaryocytic leukemia are valuable reagents for studies on these events. METHODS A new cell line, JAS-R, was established from a 64-year-old patient with acute megakaryocytic leukemia (AML M7). Its characteristics were studied by morphological, immunophenotypic and molecular biological analysis. RESULTS Immunophenotyping showed that the JAS-R cells were positive for CD33, CD41 and CD61, as well as moderately to weakly positive for CD4, CD7, CD13 and glycophorin A. Chromosomal analysis revealed a composite karyotype, but no major translocation abnormalities were observed. Electron microscopy disclosed that the JAS-R cells had numerous surface blebs and some cells also had alpha-granules and demarcation membranes. The mRNAs of 4 major proteins (platelet factor 4, beta-thromboglobulin, selectin-P and thrombospondin 1) found in alpha-granules were all expressed by the JAS-R cells. In particular, expression of platelet factor 4 was high. To further characterize JAS-R cells, comparison with 4 other megakaryo-etythroid cell lines (CMK, MEG-01, K562 and KU812) was done by gene expression profiling using an oligo-DNA microarray. The results showed that JAS-R was a distinctive cell line. It was noteworthy that the JAS-R cells secreted erythropoietin and expressed erythropoietin receptor. A neutralizing antibody for erythropoietin partly inhibited the proliferation of the cells. CONCLUSIONS JAS-R may be a useful cell line for investigating the differentiation and leukemogenesis of megakaryo-erythroid cells and for studying the influence of erythropoietin on these cells.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D007947 Leukemia, Megakaryoblastic, Acute An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common. Leukemia, Megakaryocytic,Leukemia, Megakaryocytic, Acute,Leukemia, Myeloid, Acute, M7,Megakaryoblastic Leukemia, Acute,Megakaryocytic Leukemia,Megakaryocytic Leukemia, Acute,Myeloid Leukemia, Acute, M7,Acute Megakaryoblastic Leukemia,Acute Megakaryoblastic Leukemias,Acute Megakaryocytic Leukemia,Acute Megakaryocytic Leukemias,Leukemia, Acute Megakaryoblastic,Leukemia, Acute Megakaryocytic,Leukemias, Acute Megakaryoblastic,Leukemias, Acute Megakaryocytic,Leukemias, Megakaryocytic,Megakaryoblastic Leukemias, Acute,Megakaryocytic Leukemias,Megakaryocytic Leukemias, Acute
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D020014 K562 Cells An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS. Cells, K562

Related Publications

Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
August 1988, Biochemical and biophysical research communications,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
June 1980, Proceedings of the National Academy of Sciences of the United States of America,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
January 1985, Japanese journal of cancer research : Gann,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
May 1990, The Tokai journal of experimental and clinical medicine,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
January 1981, Proceedings of the National Academy of Sciences of the United States of America,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
June 1984, Journal of immunology (Baltimore, Md. : 1950),
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
October 1993, Biology of reproduction,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
February 1994, European journal of haematology,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
January 1990, Leukemia,
Tetsuaki Sekikawa, and Satsuki Iwase, and Shinobu Saito, and Yasuhiro Arakawa, and Miyuki Agawa, and Junko Horiguchi-Yamada, and Hisashi Yamada
March 2003, Gene therapy,
Copied contents to your clipboard!